Brain Imaging Identifies Biomarkers of Mental Illness
Philadelphia | November 9, 2023
New study in Biological Psychiatry identifies predictive signature in adolescents
Research and treatment of psychiatric disorders are stymied by a lack of biomarkers – objective biological or physiological markers that can help diagnose, track, predict, and treat diseases. In a new study(opens in new tab/window), researchers use a very large dataset to identify predictive brain imaging-based biomarkers of mental illness in adolescents. The work appears in Biological Psychiatry(opens in new tab/window), published by Elsevier.
Traditionally, psychiatric disorders such as depression have been diagnosed based on symptoms according to subjective assessments. The identification of biomarkers to aid in diagnosis and treatment selection would greatly advance treatments.
In the current study, the investigators used brain imaging data from the Adolescent Brain Cognitive Development (ABCD) Study of nearly 12,000 children aged 9 to 10 at the beginning of the study. Modern neuroimaging techniques, including resting-state functional connectivity (rsFC) analysis, allow researchers to investigate the organization of brain circuits through their interaction with one another over time.
Yihong Yang, PhD, senior author of the study, at the Neuroimaging Research Branch, National Institute on Drug Abuse, said, “Using a functional MRI dataset, we identified a brain connectivity variate that is positively correlated with cognitive functions and negatively correlated with psychopathological measures.”
Cognition has long been studied in the context of mental disorders, and recent research has pointed to shared neurobiology between the two, as supported in this new study.
This brain-based variate predicted how many psychiatric disorders were identified in participants at the time of the scan and over the following two years. It also predicted the transition of diagnosis across disorders over the two-year follow-up period.”
Dr. Yang added, “These findings provide evidence for a transdiagnostic brain-based measure that underlies individual differences in developing psychiatric disorders in early adolescence.”
John Krystal, MD, Editor of Biological Psychiatry, said of the work, "Mental illness in adolescence has emerged as a cardinal public health challenge in the post-COVID era. More than ever before, we would benefit from better ways to identify adolescents at risk. This study uses data from the landmark ABCD Study to illustrate how neuroimaging data could illuminate risk for mental illness across the spectrum of diagnoses.”
Dr. Yang added, “Finding biomarkers of mental illnesses, rather than relying on symptoms, may provide a more precise means of diagnosis, and thereby aligning psychiatric diagnosis with other medical diagnoses.”
Notes for editors
The article is "Brain Functional Connectome Defines a Transdiagnostic Dimension Shared by Cognitive Function and Psychopathology in Preadolescents," by Xiang Xiao, Christopher Hammond, Betty Jo Salmeron, Danni Wang, Hong Gu, Tianye Zhai, Hieu Nguyen, Hanbing Lu, Thomas J. Ross, and Yihong Yang (https://doi.org/10.1016/j.biopsych.2023.08.028(opens in new tab/window)). It appears online as an Article in Press in Biological Psychiatry, published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected](opens in new tab/window). Journalists wishing to interview the authors may contact Yihong Yang, PhD, at [email protected](opens in new tab/window).
The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here(opens in new tab/window).
About Biological Psychiatry
Biological Psychiatry(opens in new tab/window) is the official journal of the Society of Biological Psychiatry(opens in new tab/window), whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12th out of 155 Psychiatry titles and 17th out of 272 Neurosciences titles in Journal Citation ReportsTM published by Clarivate Analytics. The 2022 Impact Factor for Biological Psychiatry is 10.6. www.biologicalpsychiatryjournal.com(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.